trending Market Intelligence /marketintelligence/en/news-insights/trending/9H7WAzS08AI9XYF8fquThA2 content esgSubNav
In This List

Anthera's kidney disease drug gets FDA orphan designation

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Anthera's kidney disease drug gets FDA orphan designation

The U.S. Food and Drug Administration granted orphan drug designation to Anthera Pharmaceuticals Inc.'s blisibimod for the treatment of immunoglobulin A nephropathy.

Blisibimod targets B-cell activating factor, which has been shown to be elevated in various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, immunoglobulin A nephropathy and others.

Immunoglobulin A nephropathy, also known as Berger's disease is characterized by deposition of immune complexes in the kidney, resulting in inflammation, the leakage of blood and protein into the urine, and loss of kidney function.